올리패스

244460KOSDAQSector: Pharma & Biotech

₩1,651 0.00%Market cap ₩13.4BAs of Jul 21, 2026 close · updated once daily

Grade F19.5 ptsTop 96% of 2,523 stocks

Financial strength

2.1

Growth momentum

61.6

Price attractiveness

9.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

2.1

How much debt does it carry relative to equity?

Debt-to-equity ratio

917.8%

✗ Below median · Top 98.2% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

10.4%

✗ Below median · Top 99.8% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-905.6%

✗ Below median · Top 95.3% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-905.0%

✗ Below median · Top 98.2% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Growth momentum

61.6

How much did revenue grow in a year?

Revenue growth (YoY)

7.9%

✓ Above median · Top 45% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

27.0%

✓ Above median · Top 31.9% in sector

Sector median 3.6%

Source filing: annual report (separate) — view original ↗

Price attractiveness

9.4

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 97.8% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

7.89x

✗ Below median · Top 83.5% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15